SAFETY, TOLERABILITY AND PHARMACODYNAMIC RESULTS OF A FIRST IN HUMAN STUDY WITH THE NEW ANTIPLATELET AGENT ACT017 FOR THE TREATMENT OF THE ACUTE PHASE OS ISCHEMIC STROKE
Christine Voors-Pette1, Peter Dogterom1, Laurie Jullien2, Martine Jandrot-Perrus3, and Gilles Avenard2
A STUDY TO DETERMINE THE POTENTIAL EFFECTS OF DISSOLUTION RATE AND FOOD ON THE PHARMACOKINETICS OF TRIENTINE 2HCL FOLLOWING SINGLE ORAL ADMINISTRATIONS IN HEALTHY SUBJECTS
Peter Dogterom1, Mireille Gerrits2, Khalid Abd-Elaziz1, Daphne van Scheppingen3, Carlot Kruse3
2In2Clinic, Wageningen, The Netherlands
3Univar B.V., Rotterdam, The Netherlands
P1-112: PROGRESSIVE INCREASE OF ALZHEIMER’S DISEASE PATHOLOGY IN 5XFAD TRANSGENIC MICE
Tina Loeffler, Magdalena Temmel, Jörg Neddens, Irene Schilcher, Birgit Hutter-Paier.
P3-113: UNTANGLING ALZHEIMER´S DISEASE HALLMARKS IN SENSORY SYSTEMS OF RODENT MODELS
Joerg Neddens1, Magdalena Temmel1, Meritxell Aguilo Garcia1,2, Tina Loeffler1, Irati Aiestaran Zelaia1, Vera Niederkofler1, Stefanie Flunkert1, Birgit Hutter-Paier1
2Institute of Molecular Biosciences, University of Graz, Graz, Austria
P4-061: TAU PHOSPHORYLATION PROFILE OF HTAU TRANSGENIC MICE
Joerg Neddens, Tina Loeffler, Magdalena Temmel, Irene Schilcher, David Amschl, Birgit Hutter-Paier
P4-062: IN VITRO MODELS TO STUDY TAU AGGREGATION, PHOSPHORYLATION AND UPTAKE
Tina Loeffler, Irene Schilcher, Stefanie Flunkert, Birgit Hutter-Paier
CHARACTERIZATION OF RELEVANT MOUSE MODELS FOR NEW BIOMARKERS
Vera Niederkofler, Tina Loeffler, Stefanie Flunkert, Agnes Kasza, Ewald Auer, Birgit Hutter-Paier
BEHAVIORAL CHARACTERIZATION OF LOW COPY SOD1 G93A TRANSGENIC MICE
Stefanie Flunkert, Roland Rabl, Agnes Kasza, Vera Niederkofler, Ewald Auer, Birgit Hutter-Paier
RELEVANCE OF CHOICE OF BRAIN REGION AND TIME POINT OF ANALYSIS AFTER MPTP LESIONING IN WILDTYPE MICE
Jan Kehr1,3, Victoria Schiffer2, Shimako Yoshitake1, Tina Loeffler2, Vera Niederkofler2, Stefanie Flunkert2, Ewald Auer2, Takashi Yoshitake3, Birgit Hutter-Paier2
CHARACTERIZATION OF 4L/PS-NA MICE FOR DIFFERENT BIOMARKERS TO MODEL GAUCHER DISEASE
Stefanie Flunkert1, Staffan Schmidt2, Tina Loeffler1, Vera Niederkofler1, Joerg Neddens1, Maria Posch1, Ewald Auer1, Jan Kehr2, Birgit Hutter-Paier1
BIOANALYTICAL MONITORING OF GENE THERAPY TRIALS: METHODOLOGIES FOR PK-PD ASSESSMENT AND PATIENT ELIGIBILITY
Fabrizia Fusetti
Fabrizia Fusetti will be making a presentation during the plenary session in the 02 Auditorium (Innovate) on Friday, November 22nd at 12:10 pm.
DETERMINATION OF MOXIFLOXACIN IN HUMAN PLASMA AND FECES BY LC-MS/MS
Martijn Hilhorst1, Violaine Augustin2, and Robbert Edens1
2Da Volterra
A DRUG-DRUG INTERACTION STUDY TO STUDY THE EFFECTS OF MULTIPLE DOSES OF THE CYP3A4 MODULATORS ITRACRONAZOLE AND RIFAMPIN ON THE SINGLE DOSE PHARMACOKINETICS OF VATIQUINONE
ChauHwei Fu, Peter Dogterom, Donald Burkindine, Thomas Chou, Christie Elliott, Martin Thoolen
A Drug-Drug Interaction Study to Study the Effects of Multiple Doses of the CYP3A4 Modulators Itraconazole and Rifampin on the Single Dose Pharmacokinetics of Vatiquinone
SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ACT017, AN ANTI-PLATELET GPVI (GLYCOPROTEIN VI) FAB IN HEALTHY VOLUNTEERS
Peter Dogterom, Christine Voors-Pette, Thomas Chou, Laurien Jullien, Kristell Lebozec, Martine Jandrot-Perrus, Gilles Avenard
INFLUENCE OF RIFAMPIN-MEDIATED OATP1B1/1B3 INHIBITION ON THE PHARMACOKINETICS OF CLAZOSENTAN
Peter Dogterom, Pierre-Eric Juif, Christine Voors-Pette, Mike Ufer, Jasper Dingemanse
A DRUG-DRUG INTERACTION STUDY: THE EFFECTS OF MULTIPLE DOSES OF THE CYP3A4 MODULATORS ITRACONAZOLE AND RIFAMPIN ON THE SINGLE DOSE PHARMACOKINETICS OF VATIQUINONE
Peter Dogterom, ChauHwei Fu, Thomas Chou, Thomas Wade, Christie Elliott, Martin Thoolen
